Cerebrospinal fluid aβ to tau ratio and postoperative cognitive change

Annals of Surgery

Volumn 258, Issue 2, 2013, Pages 364-369

  Xie, Zhongcong ^a   McAuliffe, Sayre ^a   Swain, Celeste A ^a   Ward, Sarah A P ^a   Crosby, Catherine A ^a   Zheng, Hui ^a   Sherman, Janet ^a   Dong, Yuanlin ^a   Zhang, Yiying ^a   Sunder, Neelakantan ^a   Burke, Dennis ^a   Washicosky, Kevin J ^a   Tanzi, Rudolph E ^a   Marcantonio, Edward R ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

A tau ratio; Biomarker; cognition; CSF; surgery

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ADULT; AGE; AGED; ARTICLE; CEREBROSPINAL FLUID; COGNITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; POSTOPERATIVE COGNITIVE CHANGE; POSTOPERATIVE COGNITIVE DYSFUNCTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE; SPINAL ANESTHESIA; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BIOLOGICAL MARKERS; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE PERIOD; PROSPECTIVE STUDIES; RISK FACTORS; TAU PROTEINS;

EID: 84880574050     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318298b077     Document Type: Article

References (44)

1. Moller JT, Cluitmans P, Rasmussen LS, et al. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD Investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet. 1998;351: 857-861.
2. Newman MF, Kirchner JL, Phillips-Bute B, et al. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med. 2001;344:395-402.
3. Silverstein JH, Steinmetz J, Reichenberg A, et al. Postoperative cognitive dysfunction in patients with preoperative cognitive impairment: Which domains are most vulnerable? Anesthesiology. 2007;106:431-435.
4. Terrando N, Brzezinski M, Degos V, et al. Perioperative cognitive decline in the aging population. Mayo Clin Proc. 2011;86:885-893.
5. Liu LL, Leung JM. Predicting adverse postoperative outcomes in patients aged 80 years or older. J Am Geriatr Soc. 2000;48:405-412.
6. Phillips-Bute B, Mathew JP, Blumenthal JA, et al. Association of neurocognitive function and quality of life 1 year after coronary artery bypass graft (CABG) surgery. Psychosom Med. 2006;68:369-375.
7. Steinmetz J, Christensen KB, Lund T, et al. Long-term consequences of postoperative cognitive dysfunction. Anesthesiology. 2009;110:548-555.
8. Monk TG, Weldon BC, Garvan CW, et al. Predictors of cognitive dysfunction after major noncardiac surgery. Anesthesiology. 2008;108:18-30.
9. Deiner S, Silverstein JH. Postoperative delirium and cognitive dysfunction. Br J Anaesth. 2009;103(suppl 1):i41-i46.
10. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329-344.
11. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289:2094-2103.
12. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403-413.
13. Holtzman DM. CSF biomarkers for Alzheimer's disease: Current utility and potential future use. Neurobiol Aging. 2011;32(suppl 1):S4-S9.
14. Welge V, Fiege O, Lewczuk P, et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm. 2009;116:203-212.
15. Albert MS, Moss MB, Tanzi R, et al. Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc. 2001;7:631-639.
16. Mickes L, Wixted JT, Fennema-Notestine C, et al. Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease. Neuropsychology. 2007;21:696-705.
17. Salmon DP, Thomas RG, Pay MM, et al. Alzheimer's disease can be accurately diagnosed in very mildly impaired individuals. Neurology. 2002;59: 1022-1028.
18. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed. New York: Oxford University Press; 2004.
19. Sherman JC, Leverconi C, Pollak LN. Neuropsychological assessment. In: Stern TA, Rosenbaum JF, Fava M, Biederman J, Rauch SL, eds. Massachusetts General Hospital Comprehensive Clinical Psychiatry. Philadelphia, PA: Mosby Elsevier; 2008;103-119.
20. Bateman RJ,Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloidbeta levels: Implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666-669.
21. Zhang B, Dong Y, Zhang G, et al. The inhalation anesthetic desflurane induces caspase activation and increases amyloid beta-protein levels under hypoxic conditions. J Biol Chem. 2008;283:11866-11875.
22. Bitan G, Kirkitadze MD, Lomakin A, et al. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A. 2003;100:330-335.
23. Suzuki N, Cheung TT, Cai XD, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264:1336-1340.
24. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron. 1994;13: 45-53.
25. Gravina SA, Ho L, Eckman CB, et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem. 1995;270:7013-7016.
26. Jarrett JT, Berger EP, Lansbury PT, Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993;32: 4693-4697.
27. Jarrett JT, Berger EP, Lansbury PT, Jr. The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci. 1993;695:144-148.
28. Bitan G, Vollers SS, Teplow DB. Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J Biol Chem. 2003;278:34882-34889.
29. Zhang Y,McLaughlin R, Goodyer C, et al. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol. 2002;156:519-529.
30. Mucke L, Masliah E, Yu GQ, et al. High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050-4058.
31. Mehta PD, Pirttila T, Patrick BA, et al. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett. 2001;304:102-106.
32. Lewczuk P, Esselmann H, Otto M, et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging. 2004;25:273-281.
33. Grossman M, Farmer J, Leight S, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol. 2005;57:721-729.
34. Haense C, Buerger K, Kalbe E, et al. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease. Eur J Neurol. 2008;15:1155-1162.
35. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382-389.
36. Seppala TT, Nerg O,Koivisto AM, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology. 2012;78:1568-1575.
37. Blennow K, Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis. 2009;18:413-417.
38. Benton AL, Varney NR, Hamsher KD. Visuospatial judgment. A clinical test. Arch Neurol. 1978;35:364-367.
39. CalamiaM,Markon K,Denburg NL, et al. Developing a short formof Benton's Judgment of Line Orientation Test: An item response theory approach. Clin Neuropsychol. 2011;25:670-684.
40. Tang JX, Baranov D, Hammond M, et al. Human Alzheimer and inflammation biomarkers after anesthesia and surgery. Anesthesiology. 2011;115: 727-732.
41. Fagan AM, Roe CM, Xiong C, et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343-349.
42. Palotas A, Reis HJ, Bogats G, et al. Coronary artery bypass surgery provokes Alzheimer's disease-like changes in the cerebrospinal fluid. J Alzheimers Dis. 2010;21:1153-1164.
43. Tarnaris A, Toma AK, Pullen E, et al. Cognitive, biochemical, and imaging profile of patients suffering from idiopathic normal pressure hydrocephalus. Alzheimers Dement. 2011;7:501-508.
44. Rudolph JL, Schreiber KA, Culley DJ, et al. Measurement of post-operative cognitive dysfunction after cardiac surgery: A systematic review. Acta Anaesthesiol Scand. 2010;54:663-677.